30563-98-5 Usage
Description
2-Pyridinecarboxylic acid, 5-nitro-, ethyl ester (9CI) is an organic compound that belongs to the class of pyridinecarboxylic acid esters. It is characterized by the presence of a nitro group at the 5th position and an ethyl ester group at the 2nd position of the pyridine ring. 2-Pyridinecarboxylicacid,5-nitro-,ethylester(9CI) is known for its potential applications in various industries, particularly as an intermediate in the synthesis of other compounds.
Uses
Used in Agricultural Industry:
2-Pyridinecarboxylic acid, 5-nitro-, ethyl ester (9CI) is used as an intermediate in the synthesis of 2-(pyridylcarbonyl)cyclohex-1-en-1-ol-3-ones, which are herbicides. These herbicides are employed to control the growth of unwanted plants in agricultural fields, ensuring better crop yield and quality. 2-Pyridinecarboxylicacid,5-nitro-,ethylester(9CI) plays a crucial role in the development of effective and environmentally friendly herbicides, contributing to sustainable agricultural practices.
Check Digit Verification of cas no
The CAS Registry Mumber 30563-98-5 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 3,0,5,6 and 3 respectively; the second part has 2 digits, 9 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 30563-98:
(7*3)+(6*0)+(5*5)+(4*6)+(3*3)+(2*9)+(1*8)=105
105 % 10 = 5
So 30563-98-5 is a valid CAS Registry Number.
30563-98-5Relevant articles and documents
JAK1 SELECTIVE KINASE INHIBITOR
-
Page/Page column 92-93, (2020/10/28)
Disclosed herein are compounds of Formula (I), and pharmaceutically acceptable salts thereof, that are useful as JAK kinase inhibitors. Also disclosed are pharmaceutical compositions comprising one or more compounds of Formula (I), and methods of using such compounds or compositions to treat respiratory conditions (e.g., asthma or COPD).
Antiproliferative 2-(heteroaryl)-aminothiazole compounds and pharmaceutical compositions, and methods for their use
-
Page/Page column 30, (2010/02/10)
Compounds represented by the Formula (I): are described. The compounds and pharmaceutical compositions containing them may be used in inhibiting and/or modulating protein kinases, in treating or preventing diseases associated with protein kinases, and/or in treating or preventing cellular proliferative diseases.
Synthesis of DL-slaframine
Schneider,Harris
, p. 3681 - 3684 (2007/10/02)
-